Argenica Therapeutics Ltd (AGN) - Cash Flow Conversion Efficiency

Latest as of December 2025: -1.602x

Based on the latest financial reports, Argenica Therapeutics Ltd (AGN) has a cash flow conversion efficiency ratio of -1.602x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-5.51 Million ≈ $-3.90 Million USD) by net assets (AU$3.44 Million ≈ $2.44 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Argenica Therapeutics Ltd worth for the company's overall valuation and market capitalisation.

Argenica Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2019–2024)

This chart illustrates how Argenica Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Argenica Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Argenica Therapeutics Ltd ranked by their cash flow conversion efficiency. Explore how high is Argenica Therapeutics Ltd's earnings quality to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Quoin Pharmaceuticals Ltd DRC NASDAQ:QNRX	-0.817x
Dolphin Entertainment Inc NASDAQ:DLPN	0.060x
Magnum Mining and Exploration Ltd AU:MGU	-0.164x
Malaysian Genomics Resource KLSE:0155	0.053x
DeepMarkit Corp. NASDAQ:MKTSF	0.168x
Mont Royal Resources Ltd AU:MRZ	-0.018x
CMX GOLD+SILVER CORP. F:6GS	-4.784x
Sejin T.S Co.Ltd KQ:067770	0.010x

Annual Cash Flow Conversion Efficiency for Argenica Therapeutics Ltd (2019–2024)

The table below shows the annual cash flow conversion efficiency of Argenica Therapeutics Ltd from 2019 to 2024. View Argenica Therapeutics Ltd stock quote for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	AU$7.24 Million ≈ $5.12 Million	AU$-5.70 Million ≈ $-4.04 Million	-0.788x	-117.29%
2023-12-31	AU$13.95 Million ≈ $9.87 Million	AU$-5.06 Million ≈ $-3.58 Million	-0.363x	+15.74%
2022-12-31	AU$7.67 Million ≈ $5.42 Million	AU$-3.30 Million ≈ $-2.34 Million	-0.430x	-6.38%
2021-12-31	AU$8.31 Million ≈ $5.88 Million	AU$-3.36 Million ≈ $-2.38 Million	-0.405x	-164.77%
2020-12-31	AU$6.85 Million ≈ $4.84 Million	AU$-1.05 Million ≈ $-740.40K	-0.153x	+95.22%
2019-12-31	AU$18.40K ≈ $13.02K	AU$-58.82K ≈ $-41.62K	-3.197x	--

About Argenica Therapeutics Ltd

AU:AGN Australia Biotechnology

Market Cap

$13.63 Million

AU$19.27 Million AUD

Market Cap Rank

#26352 Global

#1192 in Australia

Share Price

AU$0.15

Change (1 day)

+0.00%

52-Week Range

AU$0.09 - AU$0.34

All Time High

AU$0.99